Processa Pharmaceuticals says it is shifting its focus to immunological and inflammatory diseases following its July acquisition of Vidya Therapeutics and a concurrent private placement that raised about $200 million. The company is centering its development plan on VT-7208, Vidya’s lead investigational drug, while building a second program and adding experienced biotech executives.
The financing generated about $183.3 million in net proceeds. Processa expects that cash to fund operations into the second half of 2029, including planned Phase 2 proof-of-concept work on VT-7208 in three conditions.
Key details
-
VT-7208 is the lead program. The oral, once-daily drug is designed to inhibit Bruton’s tyrosine kinase, or BTK, a protein involved in immune-cell signaling. Processa says the candidate was designed to reach both the broader immune system and the central nervous system.
-
The planned initial indications are food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis. Processa cites estimated U.S. populations of about 17 million people with food allergies, 1.6 million to 2 million with chronic spontaneous urticaria, and about 1 million with relapsing MS. The company describes substantial unmet need in each area.
-
The CSU study has received a regulatory green light to proceed. The FDA has cleared the investigational new drug application for Processa’s planned Phase 2 trial of VT-7208 in chronic spontaneous urticaria. The letter describes a broader Phase 2 proof-of-concept plan across all three conditions, but does not give start dates or additional trial details for food allergy or relapsing MS.
-
A second program is in earlier development. Through a research collaboration and exclusive option agreement with Generian Pharmaceuticals, Processa is pursuing an oral macrocyclic peptide-based inhibitor of neonatal Fc receptor, or FcRn. The preclinical program is intended to reduce circulating IgG antibodies, including antibodies involved in autoimmune disease. Processa says it could offer an oral alternative to injectable FcRn therapies; the program remains at the preclinical stage.
-
The company has expanded its leadership team. Dr. Sheila Gujrathi has become executive chair of the board. Gregory J. Flesher was appointed chief operating officer; Craig Coburn, Ph.D., executive vice president and head of research; Ashley Hall, J.D., executive vice president of development; and Michael P. Cruse, executive vice president of business operations. Coburn helped invent VT-7208.
-
The expected share count is far above the current publicly traded common-share count. Processa lists about 2.8 million common shares currently outstanding and about 306.5 million shares issuable if its Series A non-voting preferred stock converts, for an expected total of about 309.3 million common shares on an as-converted basis. Conversion is subject to stockholder approval and applicable beneficial-ownership limits. The estimate excludes options, restricted stock units, warrants and any potential reverse stock split.
-
Stockholders will be asked to vote on multiple matters. Processa plans two separate special meetings and two separate stockholder votes. Proposals are expected to include authorizing conversion of the Series A preferred stock into common shares, matters intended to support continued compliance with Nasdaq listing standards, an increase to equity incentive plans, and other matters needed for the company to continue operating as a public company. Further details are expected in the proxy materials for the meetings.
Plain-English implications
The July transaction substantially changed Processa’s expected capital structure: the 2.8 million common shares now outstanding represent only a small fraction of the stated as-converted total. The preferred-stock conversion—and the resulting share count—depends on stockholder approval. On the development side, the financing is expected to support the company through key milestones, but VT-7208 remains investigational and its potential in the three targeted conditions has yet to be established in clinical development.